Seattle Genetics is a profounder oncology biotechnology company that serves the global market from the Pacific Northwest. The company is highly focused on commercializing and developing empowered antibodies particularly for cancer treatments. The company’s antibody-drug conjugate technology incorporates innovative linkers systems, potent cell killer agents, and monoclonal antibodies to manage cancer.
Human antibodies are part of Seattle Genetics operations, study, packaging, and manipulations. The company has excelled in antibody-therapy practices since it was first established in 1998. Antibodies developed at Seattle Genetics destroy cancerous cells from within by delivering toxin payloads. This treatment procedure has enabled Seattle to soar with competence in its niche of operation.
Seattle Genetics has managed to register a market value worth $10 billion. The company also works with over 900 employees. The recent performance enabled Seattle to rank high in Washington biotech sector. The company invests most of its resources in research, marketing, and talented human resources. One of Seattle’s flagship drug is Adcetris. This drug was specifically prepared to treat Hodgkin Lymphoma which attacks the lymph system.
Under the leadership of Clay Siegall, Seattle Genetic has become a global multi-product oncology company. He affirmed his plans of building an even greater company, with an array of drugs now under testing and research. Siegall is a visionary business person with a critical focus on drug development to meet diverse international market needs.
Siegall recently opened the company’s offices in Switzerland. This move was desirable and timely even as Seattle Genetics explores the international market. The company also entered into a partnership with Takeda. Similarly, Seattle Genetics is rapidly expanding its scale and scope of operations. The company made sales worth $418 million in 2016 registering a 46% increment within two years. Apart from Adcetris, Seattle Genetics released 33A which target acute myeloid leukemia, with rare drugs. 22ME is another drug released by Seattle Genetics to cure bladder and urothelial cancers while LIV1 is mainly for breast cancer management. Seattle Genetics has attained exemplary levels in both biomedicine and biotechnology industries.
Seattle Genetics was co-founded by Dr. Siegall in 1998. Dr. Siegall now serves as the CEO and chairperson of the company’s board of directors. Apart from his managerial role, Dr. Siegall has facilitated several fundraising activities at Seattle Genetics which have earned the company over $675 million. Between 1991 and 1997, Dr. Siegall worked with Bristol-Myers Squibb Pharmaceutical Research Institute. Finally, Dr. Siegall has registered over 15 patent and authored more than 70 publications.